NEW YORK (GenomeWeb) – Almac Diagnostics has developed a new test that can be used to identify prostate cancer patients at high risk of metastatic recurrence following treatment. The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The Craigavon, Northern Ireland-based company and partners recently published a validation study of the assay in the Journal of European Urology, demonstrating its ability to analyze formalin-fixed, paraffin-embedded samples from prostate cancer patients to identify a subgroup at higher risk of distant metastases.
According to Richard Kennedy, vice president and medical director at Almac Diagnostics, the assay could serve as an alternative to conventional means of identifying patients at risk of metastatic recurrence who have already received curative treatment for the disease, such as Gleason grade, tumor stage, or Cancer of the Prostate Risk Assessment (CAPRA) scoring.
“Although this approach is reasonably effective, it does miss a significant number of patients who go on to develop metastatic disease,” Kennedy said. “The [new] assay identifies primary tumors that have a gene expression representing metastatic biology, and may guide the use of additional therapies to prevent the development of metastatic recurrence,” he said.
Up to a quarter